Aquestive Therapeutics Inc (AQST) Directors and Executive Officers

Officers & Directors

A. Ernest Toth, Jr.
Senior Vice President, Chief Financial Officer

Timothy Morris
Member of the Board of Directors

Gregory B. Brown
Member of the Board of Directors

Marco Taglietti
Member of the Board of Directors

Santo J. Costa
Chairman of the Board of Directors

Daniel Barber
President, Chief Executive Officer and Member of the Board of Directors

Julie Krop
Member of the Board of Directors

John S. Cochran
Member of the Board of Directors

Auditor since - ,

Aquestive Therapeutics Inc currently has 147 employees.

News about Aquestive Therapeutics Inc Key Personnel

Navigating Innovation and Financial Turbulence: Aquestive Therapeutics Aims for a Breakthrough in Allergy and Epilepsy Treatment

In the fast-paced world of pharmaceuticals, where innovation often dances on the precipice of financial stability, Aquestive Therapeutics Inc. (NASDAQ: AQST) stands at a crossroads. As the company prepares to unveil new findings on its investigational drug, Anaphylm—an epinephrine sublingual film aimed at combating severe allergic reactions, including anaphylaxis—their narrative is twofold: a commitment to groundbreaking science intertwined with significant financial challenges. A Groundbreaking Approach to Allergy ManagementScheduled for presentation at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Diego from February 28 to March 3, 2025, Aquestive s Anaphylm ...

Headlining Innovation Amid Losses: Aquestive Therapeutics Charts 2025 Course with Focus on Pediatric Epilepsy Solutions

As 2025 unfolds, a spotlight shines on Aquestive Therapeutics Inc. (NASDAQ: AQST), a Warren, N.J.-based pharmaceutical company currently navigating both turbulent fiscal waters and vital advancements in pediatric neurology. The firm recently shared a multi-faceted business update underscoring its commitment to innovative drug delivery platforms and focused objectives. However, the backdrop to these ambitions is a concerning financial picture characterized by significant losses and mounting challenges.In its announcement dated January 13, 2025, Aquestive revealed a cumulative net loss of $35 million for the 12 months ending in the third quarter of 2024. This staggering deficit corresponds to a negative retur...